This technology uses drugs that stabilize β-catenin to boost protective immune cells in the lungs, reducing damage from pulmonary hemorrhage and inflammatory lung diseases by activating a novel immunomodulatory pathway.
Background: Pulmonary hemorrhage and other inflammatory lung diseases represent significant clinical challenges due to their high morbidity and mortality rates. These conditions are characterized by excessive inflammation and immune dysregulation within the lung tissue, leading to tissue damage, impaired gas exchange, and life-threatening complications. Current therapeutic strategies primarily focus on symptomatic management, such as corticosteroids and supportive care, but these approaches often fail to address the underlying immune mechanisms driving disease progression. As a result, there is a pressing need for innovative therapies that can modulate the immune response more precisely, reduce inflammation, and promote tissue repair, thereby improving outcomes for patients affected by these severe pulmonary conditions. Despite ongoing research, existing treatments for inflammatory lung diseases and pulmonary hemorrhage remain inadequate. Corticosteroids and broad-spectrum immunosuppressants, while effective at dampening inflammation, carry significant risks of systemic side effects and increased susceptibility to infections. Moreover, these therapies do not selectively target the specific immune pathways implicated in lung injury, leading to suboptimal efficacy and frequent relapses. Attempts to modulate regulatory T cell (Treg) populations have been limited by challenges in achieving tissue specificity and sustained functional enhancement. Consequently, there is a critical gap in the development of targeted immunomodulatory therapies that can provide durable protection against lung inflammation and hemorrhage without compromising overall immune competence.
Technology Overview: This technology utilizes β-catenin agonists to pharmacologically stabilize β-catenin, offering a novel therapeutic approach for protecting against pulmonary hemorrhage and other inflammatory lung diseases. The treatment works by inducing a specialized phenotype in tissue-resident regulatory T cells (Tregs) within the lung. In preclinical studies using a mouse model of lung injury, administration of β-catenin agonists led to increased lung Treg populations and significantly reduced lung damage, as evidenced by pathology and histological analysis. This method demonstrates the potential for a targeted, immune-based intervention in the management of inflammatory lung conditions, with applications for clinicians, pharmaceutical developers, and researchers in immunology and pulmonary medicine. What differentiates this technology is its ability to pharmacologically mimic the protective effects seen in genetic models of β-catenin stabilization, offering a practical and scalable therapeutic strategy. Unlike conventional anti-inflammatory treatments that broadly suppress immune responses, this approach specifically enhances a beneficial immunoregulatory pathway thereby promoting tissue protection without compromising overall immune function. The elucidation of this pathway provides a unique target for drug development, setting the technology apart from existing therapies by focusing on the modulation of tissue-resident Tregs and their role in lung repair. This targeted mechanism not only addresses a critical unmet need in pulmonary hemorrhage treatment but also opens avenues for broader applications in inflammatory disease management.
https://suny.technologypublisher.com/files/sites/adobestock_282277137.jpeg
Advantages: • Provides pharmacological protection against pulmonary hemorrhage and inflammatory lung diseases. • Induces a specialized tissue-resident regulatory T cell (Treg) phenotype to modulate immune response. • Recapitulates protective effects observed in genetic β-catenin stabilization models without genetic modification. • Demonstrated efficacy in preclinical mouse models with significant reduction of lung damage. • Potentially applicable to broader inflammatory disease management beyond pulmonary conditions. • Offers a new therapeutic approach for clinicians and pharmaceutical developers targeting lung inflammation.
Applications: • Pulmonary hemorrhage therapeutic development • Inflammatory lung disease treatment • Immunomodulatory drug discovery • Acute lung injury intervention
Intellectual Property Summary: Patent application 63/922,548 filed on 11/21/2025
Stage of Development: TRL 3. The technology is currently at a preclinical development stage, with proof of concept demonstrated through pharmacologic β-catenin stabilization and validation in relevant in vitro and in vivo lung injury models
Licensing Status: This technology is available for licensing.